Title: AI and Biotech Revolutionizing Drug Development: An Exciting Milestone in Human Trials
Introduction:
In the fast-paced world of biotechnology, a groundbreaking milestone has been achieved. Insilico Medicine, a biotech company backed by Chinese conglomerate Fosun Group and private equity giant Warburg Pincus, has successfully commenced one of the first intermediate human trials for a drug entirely discovered and designed by artificial intelligence (AI). By embracing the power of AI, Insilico aims to revolutionize the drug development process, potentially doubling the productivity of major pharmaceutical companies. This article delves into the significant advancements in AI-based drug development, Insilico’s pioneering efforts, and the potential impact on the pharmaceutical industry.
The Role of AI in Drug Development:
AI has emerged as a game-changer in the biotech industry, attracting substantial investments from Big Pharma and investors. With a market opportunity estimated to be worth $50 billion, AI tools have the potential to transform the entire drug development process. By harnessing the capabilities of AI platforms, biotech companies can process vast amounts of data to rapidly identify drug targets and design molecules with therapeutic potential.
Insilico’s Breakthrough: The First AI-Designed Drug Enters Phase 2 Clinical Trial:
Insilico Medicine, founded by Latvian scientist Alex Zhavoronkov, has achieved a vital breakthrough by initiating the Phase 2 clinical trial of a drug called INS018_055, entirely discovered and designed by AI. This novel therapy aims to treat idiopathic pulmonary fibrosis (IPF), a chronic lung disease. This milestone demonstrates Insilico’s commitment to transforming the biotech industry and represents a crucial moment for the company as it navigates uncharted territory.
The Potential Impact of Insilico’s AI Platforms:
Insilico’s AI platforms have the potential to redefine the drug discovery process. By potentially halving the time it takes to discover new drugs and significantly reducing costs, Insilico’s technology could revolutionize the pharmaceutical industry. The estimated average cost to bring a therapy to market, currently at $2.3 billion per therapy, could be significantly decreased through the adoption of AI-based approaches. Industry giants such as Sanofi, Fosun, and Johnson & Johnson have recognized the value of Insilico’s AI tools and have partnered with the company to gain access to its innovative technology.
Insilico’s Generative AI Approach:
Insilico adopts a generative AI approach, enabling rapid selection of new drug targets and molecule design to address specific diseases. By utilizing AI, Insilico can save valuable time in preclinical discovery, depending on the complexity of the target. Furthermore, AI has proven effective in improving drug success rates through enhanced chemistry and precise targeting. Additionally, AI facilitates patient recruitment, ensuring better response rates to therapy.
Challenges and Future Prospects:
Despite the promising potential of AI in drug development, uncertainties remain. Critics caution that the technology’s potential may be overstated, citing instances such as the recent failure of Benevolent AI’s main drug candidate. Nevertheless, renowned experts such as Eric Topol believe that AI already shows promise in reducing drug development time and costs. Major pharmaceutical companies have recognized this potential and have invested in AI partnerships, establishing a strong foundation for the future of AI in healthcare.
Insilico’s Commitment: A Unique Approach:
In an effort to maintain control of its flagship program and refine its AI platforms, Insilico has chosen to bring its IPF therapy into the clinic independently, rather than partnering with a large pharmaceutical company. This approach allows Insilico to generate massive amounts of data, further improving and refining their AI capabilities throughout the entire pharmaceutical R&D lifecycle.
Conclusion:
Insilico Medicine’s achievement of initiating a Phase 2 clinical trial for a drug entirely discovered and designed by AI is a remarkable milestone in the realm of biotechnology. By harnessing the power of AI, Insilico and other biotech companies are revolutionizing the drug development process. The potential to double productivity, shorten timelines, and reduce costs offers a glimpse into the transformative future of the pharmaceutical industry. While challenges and uncertainties remain, the era of AI-based drug discovery is undeniably underway. As the industry evolves, the intersection of AI and biotech promises to unlock a world of possibilities and improve healthcare outcomes.
Summary:
Insilico Medicine, a biotech company backed by Fosun Group and Warburg Pincus, has initiated a Phase 2 clinical trial for an AI-designed drug to treat idiopathic pulmonary fibrosis. This milestone highlights the potential of AI in revolutionizing the pharmaceutical industry. By utilizing AI platforms, Insilico aims to halve the time required for drug discovery, significantly decrease costs, and improve targeting and patient recruitment. While challenges remain, the convergence of AI and biotech promises to transform the drug development landscape. Insilico’s pioneering efforts showcase the significant advancements being made and the potential impact on the industry.
—————————————————-
| Article | Link |
|---|---|
| UK Artful Impressions | Premiere Etsy Store |
| Sponsored Content | View |
| 90’s Rock Band Review | View |
| Ted Lasso’s MacBook Guide | View |
| Nature’s Secret to More Energy | View |
| Ancient Recipe for Weight Loss | View |
| MacBook Air i3 vs i5 | View |
| You Need a VPN in 2023 – Liberty Shield | View |
Receive free Biotech updates
We will send you a myFT daily digest email rounding last Biotechnology news every morning.
A biotech company backed by Chinese conglomerate Fosun Group and private equity giant Warburg Pincus has embarked on one of the first intermediate human trials of a drug discovered and engineered by artificial intelligence.
Insilico Medicine, founded by Latvian scientist Alex Zhavoronkov, said it has given a patient in China a new therapy to treat the chronic lung disease idiopathic pulmonary fibrosis (IPF).
The company said the drug, INS018_055, was the first fully “discovered and designed by AI” drug to begin a Phase 2 clinical trial and represented an important milestone for the industry.
“For Insilico it is the moment of truth. . . but it is also a true test bed for TO THE and the whole industry should stand by and watch,” Zhavoronkov said in an interview.
“Our company, and it’s a big and bold claim, can double the productivity of almost any major pharmaceutical company.”
Insilico belongs to a new generation of biotechnology, who have collectively raised billions of dollars to develop AI tools to revolutionize drug development. It’s part of a rush by Big Pharma and investors to capitalize on a $50 billion market opportunity for AI in the industry, according to a Morgan Stanley report.
Zhavoronkov said Insilico’s AI platforms could potentially halve the time it takes to discover drugs and cut costs to bring drugs to market — estimated by Deloitte to $2.3 billion on average per therapy. Sanofi, Fosun and Johnson & Johnson were among several pharmaceutical companies that had signed partnership deals providing access to Insilico’s technology, he said.
AI platforms can process large amounts of data to rapidly identify drug targets – proteins in the body associated with particular diseases – and molecules that can be turned into medicines.
Several biotechs have recently announced drugs discovered or developed using artificial intelligence and machine learning tools that have moved on to clinical trials, including Exscientia, Verge Genomics, and Recursion Pharmaceuticals. Insilico uses generative AI to rapidly select new drug targets and then design new molecules that can target a particular disease.
Zhavoronkov said Insilico’s AI could save two to four years in preclinical discovery depending on the novelty and complexity of the target. He didn’t save much time in clinical development, but he improved a drug’s likelihood of success through better chemistry and better targeting. Insilico also used AI to recruit patients who were more likely to respond to therapy, he said.
There are no guarantees that the drugs AI discovers or the platforms that create them will be successful, and some critics warn that the technology’s potential is overstated. Last month Benevolent AI, a London-based biotech with an AI-powered drug discovery platform, said it would lay off 180 employees, nearly half of its workforce, following the failure of its main drug candidate.
Eric Topol, founder and director of the Scripps Research Translational Institute, said AI already showed a lot of promise in reducing the time and cost of drug development, even if regulators had not yet approved a drug entirely developed using technology.
“There is no shortage of interest. Every major pharmaceutical company has invested in partnerships with at least one, if not more, AI companies,” said Topol, author of Deep medicinea book exploring the potential of AI in healthcare.
Insilico, which has two main offices in Hong Kong and New York, has so far raised more than $400 million from a range of investors based primarily in Asia and the United States. It used AI platforms to screen 12 preclinical drug candidates, of which three progressed to clinical trials.
Zhavoronkov said the company has decided to bring its IPF therapy into the clinic itself, rather than partnering with a large pharmaceutical company, to keep control of its flagship program and refine its AI platforms.
“It is extremely important to be able to generate massive amounts of data to ensure your AI is hardened, but also to ensure that it is constantly learning,” he said. “We are pioneering new types of AI that can go from beginning to end. . . So we cover the entire pharmaceutical R&D lifecycle,” she added.
Insilico conducted Phase 1 studies of INS018_055 in New Zealand and China, which it said demonstrated favorable results supporting a Phase 2 study. This interim study will recruit 60 people with IPF in China and the United States to evaluate the safety , tolerability and preliminary efficacy of the drug.
—————————————————-